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HORMONE LEVELS IN IMMUNO-
SUPPRESSED MICE. G. WILLIAMS, R.
GHANADIAN, A. PAPADOPOULOS and J. E.
CASTRO, Royal Postgraduate Medical School,
Hammersmith Hospital, London.
Mice deficient in cell-mediated immunityby
thymectomy, irradiation and marrow recon-
stitution have been used to maintain human
tumours (Castro & Cass, 1974 Br. J. Surg., 61,
421. This may allow cytotoxic or hormonal
treatments for cancer to be tailored to indivi-
dual patients. We measured serum oestradiol,
progesterone and testosterone in male and
female immunodeficient mice aged 9 (pre-
pubertal) and 17 weeks (postpubertal) and
compared values to both normal mice and
humans.
When compared to normal mice, the only
differences in female immunosuppressed ani-
mals occurred in those aged 17 weeks, where
progesterone (P > 0-001) and oestradiol (P >
0.05) were significantly depressed. Compared
to normal human females, only levels of
testoterone in mice of both ages, and pro-
gesterone in 17-week-old mice, were similar.
When compared to normal mice, 9-week-
old male immunodeficient animals had lower
testosterone (P > 0-01) and higher proges-
terone levels (P > 0.05). In 17-week-old
mice, hormone values were similar to normals.
In miee of both ages, oestradiol was similar
to human males but levels oftestosterone and
progesterone were different.
These differences of hormone levels may
account for difficulties in the maintenance of
some "hormone-dependent" tumours. Fur-
ther investigations with hormone supple-
ments should be undertaken.
FAILURE OF NEURAMINIDASE
TREATMENT TO INFLUENCE TUMO-
RIGENICITY OF TRANSPLANTED
RAT TUMOUR CELLS. M. V. PIMM and
J. COOK, Cancer Research Campaign Labora-
tories, University of Nottingham.
There are several reports that neuramini-
dase treatment of transplanted tumour cells
reduces their growth potential (Sanford 1967,
Transplantation, 5, 1273; Currie and Bag-
shawe, 1968, Br. J. Cancer, 22, 588). This is
interpreted as being due to modification of
cell surfaces, by removal of sialic acid and/or
permanent binding of enzyme molecules,
increasing tumour-cell immunogenicity (Rios
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and Simmons, 1974, Int. J. Cancer, 13, 71;
Sedlacek and Seiler, 1974, Behring Inst. Mitt.,
55, 254). Other workers have failed to confirm
these findings, and ascribe them only to non-
specific toxicity (Yuhas et al., 1974, J. natn.
Cancer Inst., 53, 665; Froese et al., 1974, J.
natn. Cancer Inst., 52, 1905). In the present
tests, the influence of Vibrio cholerae neurami-
nidase (VCN) (Behringwerke) on the growth
of a range of rat tumours has been examined.
In vitro incubation under standard conditions
(5-25 units/106 cells, 30 min, 37°C at pH 5-6)
released 0-2-1-0 jumol sialic acid/109 cells,
but consistently failed to reduce their in vivo
tumorigenicity. With all of 7 tumours exa-
mined (sarcomas, hepatoma, mammary car-
cinoma and epithelioma) incidences and
growth rates were identical to those from
untreated cells and/or cells exposed to only
pH 5-6 buffer. Furthermore, rats receiving
repeated injections of VCN-treated, y-irradi-
ated cells of a poorly immunogenic mammary
carcinoma showed no augmented immunity
to challenge, and the efficiency of mixed
inocula of MCA-induced sarcoma cells and
adjuvants for active immunotherapy was
not improved by their VCN pretreatment. In
summary, these studies are unable to con-
firm the reduced tumorigenicity of VCN-
treated cells, or their increased immuno-
genicity.
IMMUNOPROTECTION AGAINST
METHYLCHOLANTHRENE FIBRO-
SARCOMAS WITH TERATOCAR-
CINOMA CELLS. P. L. STERN, K. SIKORA
and E. LENNOX. M.R.C. Molecular Biology
Laboratory, Hills Road, Cambridge.
Methyleholanthrene-induced sarcomas
(MCS) in mice often possess individually
specific transplantation antigens. Such anti-
gens have been demonstrated by in vivo pro-
tection assays in xvhich mice immunized with
a tumour are subsequently challenged with
the same or a different tumour. Although
serological studies have shown such sarcomas
possess common embryonic and viral anti-
gens, only occasional weak cross-protection
in vivo between different MCS's has been
described. However, there are reports of
protection in vivo by immunization with
mid-term embryonic cells. Embryonal car-
cinoma cells, the stem cells of teratocar-
cinomas, show remarkable similarities to the
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pluripotent cells of early mouse embryos, in-
cluding morphological, biochemical and cell-
surface antigenic properties. We show that
effective immunization against several dif-
ferent non-cross-reacting sarcomas, including
one not immunogenic itself, can be achieved
with embryonal carcinoma cells. In addition,
protection can also be achieved by immuniz-
ing with endodermal cells derived from em-
bryoid bodies made by pluripotent embryonal
carcinoma cells.
SOLUBILIZATION AND PARTIAL
CHARACTERIZATION OF TUMOUR-
SPECIFIC TRANSPLANTATION
ANTIGENS FROM CHEMICALLY
INDUCED SARCOMAS. K. SIKORA, G.
KOCH and E. LENNOX, M.R.C. Laboratory of
Molecular Biology, Hills Road, Cambridge.
The induction with methylcholanthrene of
sarcomas in mice usually produces tumours
which do not cross-react in protection assays,
indicating that the tumour-specific trans-
plantation antigens are extremely diverse.
Elucidation of the genetic and molecular
sources ofthis diversity requires the purifica-
tion and characterization of the antigens.
This report describes the isolation of the
antigens in a form suitable for purification.
Two highly immunogenic, individually
specific tumours were induced in opposite
limbs of a single mouse. Purified plasma
membranes from the tumours retained the
specific protective capacities. The membranes
were solubilized with the detergent sodium
deoxycholate. Two serologically detectable
membrane components, H2 and an antigen
common to the sarcomas which is detected
with syngeneic antitumour sera, were quan-
titatively solubilized by this technique. The
deoxycholate-solubilized material was also
specifically immunogenic in protective assays
showing that the tumour-specific transplanta-
tion antigens can be solubilized. The solubil-
ized antigens were purified further on columns
of immobilized lectins.
LYMPHOCYTOTOXICITY AGAINST
AUTOLOGOUS HUMAN BIOPSY
CELLS. B. M. VOSE, F. VANKY and E.
KLEIN. Paterson Laboratories, Christie Hos-
pital & Holt Radium Institute, Manchester and
Department of Tumor Biology, Karolinska
Institute, Stockholm.
Cell preparations with high viability and
low host-cell contamination have been pre-
pared from human tumour biopsies and used
as targets in 5lCr-release cytotoxicity assays.
Autologous lymphocytes from blood and,
when possible, from the draining lymph node
and within the tumour were used as effectors.
Significant reactivity was determined in 11/30
blood lymphocytes. Tests with 4 benign
conditions were negative. Reactivity in the
draining lymph node largely paralleled that
in the blood, but tumour-infiltrating lympho-
cytes were generally non-reactive against
autologous biopsy cells although responses to
PHA and in MLC were detectable. Cyto-
toxicity against K562 (a long-term culture
line known to be sensitive to natural killer
activity) was frequently detected in blood
lymphocytes but only rarely in the lymph
node and tumour lymphocytes. Similar pat-
terns of reactivity were detected when the
autologous tumour stimulation assay was
used. Increased uptake of 3H-thymidine
following exposure to autologous biopsy cells
was revealed in 6/11 blood preparations 7/10
lymph nodes and 1/7 tumour-infiltrating
lymphocytes.
IMMUNOLOGICAL STATUS OF
PATIENTS WITH CARCINOMA OF
THE CERVIX. A. M. SAVAGE, J. A. V.
PRITCHARD and K. W. JAMES. Tenovus
Laboratories, South Wales Radiotherapy and
Oncology Service, Velindre Hospital, Whit-
church, Cardiff.
The effects of radiotherapy on patients
with carcinoma of the cervix at different
stages was assessed by lymphocyte trans-
formation with PHA, T and B rosettes and
analysis of peripheral blood films. Blood
samples were taken before and after radio-
therapy treatment and at the first follow-up
clinic. A normal range of values was obtained
from healthy donors for comparison.
Preliminary results indicate that there is a
difference in T and B rosetting between
normals and patients with cancer of the cer-
vix. Radiotherapy appears to diminish the
percentage T cells and cell yields. Comparison
between stages show a tendency for T cells to
be depleted in the later stages. PHA trans-
formation has not shown any significant
differences between the groups.
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THE USE OF TANNED STABILIZED
SHEEP ERYTHROCYTES TO DEMON-
STRATE LYMPHOCYTE SENSITIZA-
TION. J. J. SMITH and J. A. V. PRITCHARD.
South Wales Radiotherapy and Oncology Ser-
vice, Velindre Hospital, Whitchurch, Cardiff.
Sheep erythrocytes, treated with tannic
acid and stabilized with sulphosalicylic acid,
have been used in the Cell Partition assay (as
described by Smith and Dickinson, 1976,
Lancet, ii, 1336) to demonstrate lymphocyte
sensitization to encephalitogenic factor (EF)
derived from human brain for normal sub-
jects and cancer patients. Mixed-lymphocyte-
reaction assays can also be performed using
this system.
Preliminary results indicate that patients
with a variety of malignant diseases have
lymphocyte sensitization to EF, which is
shown as a reduction in partition coefficient.
For normal subjects, a corresponding increase
in partition coefficient has been found.
NON-CROSS-REACTIVITY OF AN
ANTI-FOETAL-LUNG SERUM WITH
HUMAN LUNG CANCER CELLS IN
AN INDIRECT IMMUNOFLUORES-
CENCE TEST. C. H. J. FORD, J. HET-
TIARACHCHI and C. E. NEWMAN. Surgical
Immunology Unit, Department of Surgery,
University ofBirmingham.
Cross-reactivitybetweenfoetalantigens and
antigens of malignant cells has been reported
in human lung cancer (Bell, 1976, Cancer, 37,
706). In this study an antiserum was raised
to human foetal lungandextensivelyabsorbed
to remove haemagglutinating, haemolytic,
lymphocytotoxic and antiplatelet antibodies.
Sequential absorptions with human spleen
and thymus were monitored by lympho-
cytotoxicity and immunofluorescence with
human peripheral-blood lymphocytes. The
unabsorbed and 4 x absorbed samples were
widely cross-reactive with human lung can-
cers, foetal andadultnormaltissues. However,
the 9x absorbed serum, negative with lym-
phocytes by both cytotoxicity and immuno-
fluorescence, selectively localized on foetal
bronchial epithelial cells but not on human
lung cancers ofoat-cell, anaplastic, squamous
or adenocarcinoma cell types. Previously we
have demonstrated that antisera to human
lung tumours selectively localize on lung
cancer cells and that an anti-oat-cell serum
contained high titres of anti-tumour and
anti-CEA antibodies (Newman et al., 1977,
Proc. 18th Annual General Meeting of the
BACR). Removal of anti-CEA antibody does
not alter the anti-tumour activity. The pre-
sent study suggests that the cross-reactivity
seen in the under-absorbed anti-foetal anti-
serum is due to shared normal antigens, and
that there are specific foetal antigens not
present on normal or malignant human tis-
sues. This finding, together with the selec-
tivity of anti-lung-cancer sera for lung can-
cer cells, after removal ofantibodies to normal
and onco-foetal antigens, suggests thathuman
lung cancer cells also express specific cell-
surface antigens.
IMMUNE COMPLEXES IN BREAST
CARCINOMA. R. A. ROBINS, K. H6FFKEN,
C. J. DAVES and R. W. BALDWIN. Cancer
Research Campaign Labs., University of
Nottingham.
Plasma samples from patients undergoing
simple mastectomy for primary breast car-
cinoma were tested for immune complexes
by a modified Clq-binding assay (Zubler etal.,
1976, J. Immunol., 116, 232). Tests were per-
formed on samples taken preoperatively and
12 months postoperatively from three groups
ofpatients: a group having no tumour detect-
able histopathologically in the axillary or
internal mammary lymph nodes (good prog-
nosis); a group having tumour detected in
nodes from the apex of the axilla or internal
mammary chain (poor prognosis); and a
smallgroupofpatientsdyingwithin22months
of mastectomy. Preoperative samples from
all three groups of patients gave significantly
higher Clq binding than in control samples
from normal age-matched women. Moreover,
post-mastectomy samples from good-prog-
nosis patients were in the normal range,
whereas samples from poor-prognosis patients
and those with a short survival remained
significantly elevated after mastectomy. Pre-
liminary results indicate that recurrence may
be accompanied by raised serum Clq-binding
activity. These findings indicate that Clq-
binding activity of plasma may be useful in
determination of status of disease in primary
breast carcinoma.
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A STUDY OF THE MECHANISM OF
ACTION OF ANTITUMOUR DIME-
THYLTRIAZENES. J. A. HICKMAN and
K. VAUGHAN, Cancer Chemotherapy Group,
Department ofPharmacy, University of Aston,
Birmingham.
It has been proposed that the mechanism of
action in vivo of dimethyltriazenes may in-
volve their metabolic N-demethylation to
monomethyltriazenes (which are alkylating
agents) since monomethyltriazenes are cyto-
toxic in vitro whereas dimethyltriazenes are
not (Connors et al., 1976 Biochem. Pharmac.
25, 241). However, there is some evidence
which suggests that the dimethyltriazenes
may not owe their activity in vivo to the for-
mation of an alkylating agent; for example
they are active against a tumour which is
naturally resistant to alkylating agents
(Connors and Hare, 1975 Biochem. Pharnac.
24, 2133). Using a bioassay system we have
compared the cytotoxicity of a monomethyl-
triazene to TLX5 cells and TLX5/R cells
(which have had resistance to dimethyl-
triazenes induced in vivo) and found no
difference between them. The cytotoxicity of
a monoethyltriazene was found to be of the
same order as for the monomethyl, although
the diethyltriazenes have no in vivo anti-
tumour effect, despite undergoing N-de-
ethylation. The results suggest that mono-
alkyltriazenes are nonselective cytotoxic
agents.
COENZYMES AND TUMOUR CHEMO-
THERAPY BY ALKYLATING AGENTS.
R. SCHOENTAL, Royal Veterinary College,
London.
Tumour chemotherapy is often bedevilled
by the unexplained variability of response of
individual patients to any schedule of treat-
ment, even when the tumour characteristics
appear to be similar. In the case of alkylating
agents this may be due to the nutritional
status of the patient, especially to the levels
of B vitamins and of the various forms of
coenzymes (such as NAD, FAD, CoA,
folates, etc) which on alkylation of their
reactive nucleophilic groups become inacti-
vated, so that the respective enzymes are no
longer able to exert their vital biochemical
functions (compare: Schoental, 1976, FEBS
Letters, 61, 111; Schoental and Cavanagh,
1977, Neuropath. Appl. Neurobiol., 3, 145;
Schoental, 1977, Biochem.Soc.Trans.,5, 1016).
As the concentrations of these coenzymes
are usually lower in tumours than in the cor-
responding normal tissues, their differential
depletion in tumours would lead to the in-
hibition of tumour growth and necrosis,
without significant deleterious effects on
normal tissues. Estimation ofcoenzymes may
lead to appropriate quantitation ofdosage on
a scientific basis in each case.
SIMULTANEOUS ESTIMATION OF
RNA AND DNA IN POPULATIONS OF
INDIVIDUAL CELLS. J. V. WATSON, N. M.
BLEEHEN and S. H. CHAMBERS, M.R.C.
Clinical Oncology and Radiotherapeutics Unit,
Cambridge.
A recently developed staining technique
using acridine orange enables RNA and DNA
to be estimated simultaneously in individual
cells (Traganos et al., 1977, J. Histochem.
Cytochem., 25, 46). These methods have been
used in vivo to demonstrate that the RNA
content in a "more" clonogenic fraction of
EMT6 mouse tumour cells, separated by the
method of Twentyman and Watson, 1977
(Br. J. Cancer, 35, 120) is higher than in a
"less" clonogenic fraction. In vitro studies
have shown that the RNA content of ex-
ponentially growing EMT6 cells is higher
than that of late-plateau cells. Following
mitotic-selection synchronization we have
found that the RNA levels increase during
GI, but remain virtually constant in early
and mid S. However, a second rapid increase
in RNA levels occurs during late S. These
results were parallelled by changes in the
rate of 3H-UdR uptake as measured by auto-
radiography.
STUDIES ON THE PHARMACOKINE-
TICS OF MISONIDAZOLE (Ro 07-0582)
IN MAN USING HIGH-PRESSURE
LIQUID CHROMATOGRAPHY (HPLC)
ANALYSIS. P. WORKMAN, C. R. WILTSHIRE,
J. V. WATSON and N. M. BLEEHEN, M.R.C.
Clinical Oncology and Radiotherapeutics Unit,
Hills Road, Cambridge.
Methodology has been established for the
specific assay of the hypoxic cell sensitizer
Misonidazole (1-(2-nitroimidazol-1-yl)-3-
methoxypropan-2-ol; Ro 07-0582) and its
0-demethylated metabolite (1-(2-nitroimi-
dazol-1-yl)-2,3-propandiol; Ro 05-9963) in
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biological materials, using reverse-phase high-
pressure liquid chromatography (HPLC).
In 10 patients with malignant disease
receiving 3 g/m2 Misonidazole orally, typical
plasma levels of 120 ,tg/ml were observed
1-4 h after administration. Tumour levels
estimated in a patient with carcinoma of the
breast were in the range 50-70% of the cor-
responding plasma values. Concentrations of
Ro 05-9963 in plasma and tumour were
normally .10% of those of the parent drug.
Radiotherapy was given at 4 h and signifi-
cant radiation enhancement ratios would be
expected under these conditions.
5-FLUOROURACIL PHARMACOKINE-
TICS IN PATIENTS ON COMBINA-
TION CHEMOTHERAPY FORBREAST
CANCER. H. W. VAN DEN BERG and R. F.
MtrRPHY, Dept. Biochemistry, Queen's Univer-
sity, Belfast.
We have used a novel GLC-electron-cap-
ture assay to monitor the plasma concentra-
tion of 5-fluorouracil (5-FU) in patients
undergoing combination chemotherapy for
breast cancer. The lower limit ofdetection by
this technique is 20 ng 5-FU/ml plasma.
Drug regimes consisted of 5-FU and vin-
cristine, together with either adriamycin or
cyclophosphamide. Semi-logarithmic plots of
5-FU plasma concentration against time
revealed a biexponential disposition pattern.
A rapid-distribution phase (ti = 28-7-2 min,
mean 5`5 min), was followed by a slower
phase, (tl - 6-9-218 min, mean 12-5 min)
representing metabolism and excretion. The
apparent volume of distribution of 5-FU at
time zero ranged from 4 0 to 21-81, reflecting
individual differences in the extent of ab-
sorption of the drug by tissues. A second
peak appeared in GLC elution profiles of
plasma extracts within 15 min of drug
administration. The identity of this peak is
unknown, but its chromatographic behaviour
suggests it may represent 5-6 dihydro-
fluorouracil, a known catabolite of5-FU.
ANTI-CARCINOGENIC PROPERTIES
OF VITAMIN A AND ITS STRUC-
TURAL ANALOGUES STUDIED IN
ORGAN CULTURE. I. LASNITZKI, Strange-
ways Research Laboratory, Cambridge.
The interaction ofvitamin A and its struc-
tural analogues with methyleholanthrene
31*
was investigated in mouse prostate glands
grown in organ culture.
Methylcholanthrene stimulates cell divi-
sion, resulting in extensive hyperplasia,
squamous metaplasia and dysplasia of the
prostatic epithelium. These changes persist
after withdrawal ofthe carcinogen.
The vitamin A compounds examined were
retinol, retinoic acid and 9 of its structural
analogues synthesized in an attempt to in-
crease the anti-carcinogenic activity and to
lower the toxicity of their parent compound.
These included the cyclopentenyl analogue
of retinoic acid, a-retinoic acid,- A2-retinoic
acid, 13cis cx-retinoic acid and 6 aromatic
analogues.
The compounds were either added to the
culture medium simultaneously with methyl-
cholanthrene or administered to explants
which had been pretreated with the carcino-
gen.
If combined with the carcinogen, the com-
pounds inhibited the hyperplasia to a striking
degree; if applied following exposure to the
carcinogen they reversed epithelial hyper-
plasia and metaplasia and largely restored a
normal pattern ofgrowth.
The inhibitory effect of most of the analo-
gues was similar to or greater than that of
their parent compound, and seemed to be
caused by a reduction ofDNA synthesis. The
effect was not due to a reduced uptake or
increased release of the carcinogen by the
vitamin-A-treated tissue. It also appeared
unrelated to the biological growth-promoting
activity of the compounds or their surface-
active properties.
ASSESSMENT OF THE TOXICITY OF
RETINOIDS IN ORGAN CULTURE.
D. R. BARD and I. LASNITZKI. Strangeways
Research Laboratory, Worts' Causeway, Cam-
bridge.
Although Vitamin A and retinoic acid are
well known to oppose carcinogenesis in a
number of different systems, their toxicity
at therapeutic concentrations has limited
their clinical use. Some structural analogues
also have anticarcinogenic activity (Lasnitzki,
1976, Br. J. Cancer, 34, 239) and the present
study was undertaken to assess the toxicity
of these compounds towards tissues by
measuring the degradation of cartilage in
vitro.
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The release of 3584- from pre-labelled
rabbit ear cartilage in the presence of 19
retinoids wAas measured by a method pre-
viously described (Bard and Lasnitzki, 1977,
Br. J. Cancer, 35, 115). Compounds retaining
a carboxylic-acid group were found to be
most active in releasing sulphate, whereas
esters, substituted amides and ethers caused
much less breakdown of the tissue. Altera-
tion of the molecule from the 13-trans to the
13-cis configuration and several modifica-
tions of the hexenyl ring had little effect on
the activity towards cartilage.
The identification of compounds, such as
the methyl ether of all-trans-/-retinol, which
combine anti-carcinogenic properties with
minimal activity in degrading cartilage,
raises considerable hope for the development
of a useful chemotherapeutic agent.
SCREENING SAMPLES OF HUMAN
ASTROCYTOMA FOR DRUG SENSI-
TIVITY BY SCINTILLATION AUTO-
FLUOROGRAPHY. D. MORGAN, R. I.
FRESHNEY. Beatson Institute for Cancer
Research, Glasgow; D. G. T. THOMAS, Institute
of Neurology, University of London and
D. I. GRAHAM, Institute of Neurological
Sciences, Glasgow.
Previous reports (Davison, Dendy and
Mitchell, Oncology, in press) have suggested
significantly improved survival of ovarian
carcinoma patients by using an in vitro
tissue-culture predictive test of chemothera-
peutic agents. Cultures derived from human
glioma were predominantly dividing, aneu-
ploid, astrocyte-like cells, unlike cultures
from other solid tumours which were over-
grown by stromal fibroblasts. Biopsies were
digested with collagenase (Freshney, R. I.,
1972, Lancet, ii, 488) and monolayer cul-
tures grown in microtitration plates. Drugs
were added for 3 days during exponential
phase, and the 5000 inhibitory dose (ID50)
monitored for several weeks.
Previous results (Freshney, Paul and Kane,
1975, Br. J. Cancer, 31, 89) obtained using
HeLa cells, showed maximum ID50 4-5 days
after drug removal, but due to the longer
doubling time ofglioma cells, some drugs (e.g.
BCNU) required up to 4 weeks to achieve a
stable ID50. Lengthening the assay also
allowed resistant sub-populations to be
detected.
To give faster predictions a new test based
on scintillation autofluorography was de-
veloped. Cells were labelled with 35S-
methionine, fixed in methanol, extracted with
TCA and scintillator added to each well. The
solvent was dried off with centrifugation and
the plate was then exposed to Kodak RP
X-Omat X-ray film, and the density of the
resultant spots measured using a Chromoscan
Densitometer. The ID50 may then be derived
directly from the density plot.
Using these methods a clinical recommen-
dation could be made 6-8 weeks after surgery.
TUMOUR-VOLUME RESPONSE AND
CELLULAR REPOPULATION IN B16
MELANOMA TREATED WITH VARI-
OUS CYTOTOXIC DRUGS. T. C. STE-
PHENS, J. H. PEACOCK and G. G. STEEL, Inst.
Cancer Research, Sutton, Surrey.
The relationship between tumour-volume
response and cell kill in subcutaneous B16
melanomas treated with cyclophosphamide,
CCNU and melpha]an was investigated.
Tumour-volume response, expressed as
growth delay, was estimated from measure-
ments of tumour dimensions. An in vitro
colony-forming assay was employed to mea-
sure cell survival. When cell survival at 18 h
after drug administration was compared to
growth delay, considerably more delay per
decade reduction in cell survival was achieved
with cyclophosphamide (--75 days) than
with either CCNU or melphalan (both ,2-5
days). Since this may reflect differing patterns
of recovery after these agents, cellular re-
population was assessed directly by per-
forming cell-survival assays at various times
after treatment with doses of the agents
which each produced an equal reduction in
cell survival measured at 18 h. The rate of
repopulation of clonogenic cells was much
slower after treatment with cyclophospha-
mide (Td ~-1 5 days) than with either CCNU
or melphalan (Td's ~0-8 days) and this
appears to account for the longer duration of
growth delay obtained with the former agent.
INDUCTION OF A HEXAPLOID EMT6
TUMOUR BY RAZOXANE (IRCF 159).
I. W. TAYLOR and N. M. BLEEHEN, M.R.C.
Unit of Clinical Oncology and Radiotherapeu-
tics, Hills Road, Cambridge.
Using the EMT6 cell line grown in vitro, we
have shown that Razoxane prevents cell
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division, while allowing synthesis of nuclear
DNA to continue (Taylor and Bleehen, 1977,
Br. J. Cancer, 35, 587). The nuclear DNA
content is twice normal after a 24 h exposure
to Razoxane, and continues to increase as
long as the drug is present. If, however, the
drug is removed at 24 h, the cells eventually
divide and begin to proliferate, but they
maintain double the usual triploid comple-
ment of nuclear DNA in untreated EMT6
cells. A stable hexaploid cell line, cloned from
cells treated in this way, has now been main-
tained continuously in culture for >6 months.
Chromosome analysis show these cells to have
'130 chromosomes, compared with 68 for
normal EMT6 cells. The response of this
hexaploid cell line to radiation and to
Razoxane does not appear to differ greatly
from that found for EMT6.
A hexaploid EMT6 tumour capable of
growth in vivo has been derived from triploid
cells taken from normal EMT6 tumours and
suitably treated with Razoxane in vitro.
ENHANCEMENT BYHYPERTHERMIA
OF THE EFFECT OF BCNU ON THE
EMT6 MOUSE TUMOUR. P. R. TWENTY-
MAN, J. E. MORGAN and J. DONALDSON,
M.R.C. Clinical Oncology and Radiotherapeu-
tics Unit, Hills Road, Cambridge.
The combination ofmoderate hyperthermia
(43°C water bath for 1 h) and 1,3 Bis (2-
chloroethyl)-l-nitrosourea against the EMT6
mouse tumour has been studied. The effect
was found to be much greater than would
have been predicted from the effects of the
single modalities, and this is true whether
the end point be tumour cure, growth delay,
or in vitro assay of clonogenic fraction. The
results indicate that inhibition of "recovery
from potentially lethal drug damage" is not
the mechanism by which heat potentiates the
action of BCNU.
IDENTIFICATION OF PATHOGENIC
FUNGI IN HUMAN MYCOSES BY THE
USE OF LECTINS. *R. W. STODDART and
tB. M. HERBERTSON, *Strangeways Res.
Lab. Cambridge. tDept. Pathology, Tennis
Court Road, Cambridge.
Mycoses are among the most intractable
infections in the immunodeficient patient.
They are important and often fatal complica-
tions of some leukaemias and lymphomas and
they may also arise in patients whose immune
systems have been injured by cytotoxic drugs.
The rapid identification of the infecting
species is essential. This usually requires
culture, especially where histological evi-
dence is insufficient. Problems arise where
culture is impossible or fails or where un-
certainty remains as to the identity of the
species grown with that seen in histological
sections.
Differences in the carbohydrates of the cell
walls of the various species can be exploited
by use of fluorescein-labelled lectins, to cir-
cumvent these difficulties. Thus, Candida
albicans stains strongly and selectively with
concanavalin A for o-ID-mannose, Asper-
gillus fumigatus, with soy-bean agglutinin for
/3-D-N-acetylgalactosamine and Cryptococcus
neoformans with aprotinin probably for
glucuronic acid. Mucor, Blastomyces and
Paracoccidiodes can similarly be distinguished
using these and other lectins specific for
fl-D-galactose, /-D-N-acetylglucosamine and
a-L-fucose. The method is simple, rapid and
practical.
MELPHALAN AND STEROID HOR-
MONES. J. M. ANDERSON, T. ALGIE, J. K.
GRANT and G. GETTINBY, Royal Infirmary
and Universities of Glasgow and Strathclyde,
Glasgow.
Striking differences in chemotherapy-
related delay of recrudescence of mammary
cancers in premenopausal and in postmeno-
pausal women have been described in two
recent trials (Fisher et al., 1975, New Engl. J.
Med., 292, 117; Bonadonna, Symposium of
British Association of Surgical Oncology,
Dec. 17, 1976). The longer cancer-free interval
in premenopausal women may result from
direct or pituitary-mediated suppression of
ovarian functions. However, no significant
differences in plasma oestradiol and andro-
gens at both follicular and luteal phases have
been observed in 6 node-positive patients
menstruating regularly, during monthly 5-
day pulses of oral melphalan. The differences
between follicular and luteal levels of oestra-
diol were, as expected, statistically significant
(P< 0.05) in a Mann-Whitney U test, con-
firming the need to study putative chemo-
therapeutic effects at these phases separately.
Unexpectedly, plasma oestradiol levels
were lower after similar pulses of melphalan
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in 6 node-positive postmenopausal patients
(P < 0 05 in Mann-Whitney U test) indicat-
ing that, although steroid hormones may be
influenced by melphalan, an uncomplicated
suppression of premenopausal ovaries is not
the only factor worthy of investigation.
MODULATION OF ALKYLATING
AGENT TOXICITY AND ANTITUM-
OUR EFFECT BY STEROIDS. R. WIL-
KINSON and K. R. HARRAP, Inst. of Cancer
Res., Sutton, Surrey.
Prednisolone is frequently included in
clinical treatment schedules with alkylating
agents, where tumouricidal effects could be
expected from both components. We have
previously shown, however, that predniisolone
in combination with chlorambucil potentiates
cytotoxicity against cells in which predniso-
lone alone has no effect (Harrap et al., 1977,
Eur. J. Cancer, 13. More recent studies
indicate that prednisolone may be combined
with other alkylating agents with beneficial
effects. By combining prednisolone with
nitrogen mustard it is possible to suppress
the toxicity of the alkylating agent, whilst
enhancing its antitumour effect. In the case
of binary combinations of melphalan and
prednisolone, both toxicity and antitumour
effect are increased above those ofthe alkylat-
ing agent alone. These effects are closely
dependent upon schedule design and, by
administering the steroid after the alkylating
agent, toxicity can be reduced with no loss
ofantitumour effect. Insensitivecells, alkylat-
ing agent cytotoxicity is accompanied by
morphological dissociation of chromatin and
changes in nuclear protein integrity, which
are not detected in resistant cells. However,
binary combinations of alkylating agents and
steroids are cytotoxic in resistant cells, and
elicit a biochemical response typical of the
sensitive cells. It is proposed that these
experimental observations may provide a
more rational basis for the design of clinical
treatment schedules.
THE MODE OF ACTION AND BIO-
LOGICAL EFFECTS OF CERTAIN
ANTITUMOUR DRUGS AND ANTI-
FERTILITY AGENTS IN XENOPUS
LAEVIS AND MUS MUSCULUS. B. N.
HEMSWORTH and A. A. WARDHAUGH, Life
Science Laboratory, Teesside Polytechnic,
Middlesbrough.
Using an in vitro toad system, described by
Jones and Jackson (1974, J. Reprod. Fertil.,
38, 347) for the detection and study of chemi-
cal mutagens able to affect post-meiotic germ
cells, we have found that exposure of sperm
to the isomeric forms of dimethylmyleran,
MMS, gamma radiation and nicotine leads to
embryopathy. In high concentration, various
steroids have an antifertility action due to
impaired sperm motility. Studies indicate
that lower concentrations are compatible with
fertility and production of apparently normal
offspring.
In Mus musculus, the isomeric forms of
dimethylmeran have an antifertility action
referable to interference with spermatogonia,
spermatocytes and post-meiotic germ cells.
CHEMOTHERAPY OF PIG LYMPHO-
MA. S. E. BROWNLIE, J. G. CAMPBELL,
K. W. HEAD, P. IMLAH, andH. S. McTAGGART,
Faculty of Veterinary Medicine, University of
Edinburgh, and J. G. MCVIE, Department of
Clinical Oncology, University of Glasgow.
A preliminary report at the BACR meeting
in March 1977 described experiments to
investigate the applications of pigs with
hereditary lymphoma (Head et al., 1974,
Vet. Rec. 95, 523) as a chemotherapy model
for man. Cases have been given single-agent
therapy, after toxicity tests. Prednisolone
intramuscularly (4 cases) and orally (2 cases)
for 5 weeks, was shown to improve vigour
and appetite, red-cell picture, neutrophil and
platelet counts. Circulating tumour-cell
counts and lymph-node size were reduced to
normal. Relapse occurred 5 weeks after with-
drawal of the drug. One 18-month-old pig
was treated for 2 months with prednisolone
and improved dramatically, but after another
2 months became recumbent and refused to
eat. Autopsy showed a lymphomatous mass
in the meninges pressing on the brain. Tum-
our has not been seen at this site in any of 50
untreated cases, and it provides a good
analogy to lymphocytic leukaemia inchildren.
An almost moribund 4-month-old female
improved on treatment with prednisolone,
followed by vincristine and cyclophospha-
mide. The last two drugs given 48 h apart
showed better results than when given
simultaneously. Remission was maintained
for over a year and the pig looked normal.
It show%ed regular oestius, which is not seen
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in untreated eases. Side effects from cyclo-
phosphamide are almost identical to those
in man, particularly a consistent reversible
neutropenia at Days 6-8. Vincristine caused
hindleg ataxia in the pig and doxorubicin
produced liver failure, alopecia, nail changes
and cardiotoxicity. The therapeutic response
and comparable side effects to cytotoxic
drugs suggest that the pig lymphoma is a
useful model for testing new agents and
combinations.
COMBINATION CHEMOTHERAPY IN
MALIGNANT MELANOMA. M. SOUKOP,
K. C. CALMAN, J. G. MCVIE and R. MAcKIE,
Department of Clinical Oncology, Glasgow.
The aim of this study was to compare two
regimes of combination chemotherapy in
disseminated malignant melonoma. All
patients had biopsy-proven disease, and sites
of involvement incJuded skin, lymph nodes,
liver, brain and lung. Response was defined
by the standard criteria used by the Eastern
Cooperative Oncology Group.
The first regime consisted for DTIC (200
mg/M2 i.v. daily for 5 days) together with
methyl CCNU (100 mg/M2 orally on Day 1)
and vincristine (1 mg/M2 i.v. on Day 1) the
regime being repeated at 3 or 4-weekly inter-
vals. Toxicity was mainly related to nausea
and vomiting. Fourteen patients were treated
and all were evaluable. There was one partial
response.
The second regime was chosen fortuitously
and, because a response was obtained, it was
evaluated in a series of patients. This drug
regime consisted of adriamycin (50 mg/M2
i.v. Day 1) cyclophosphamide (500 mg/M2
i.v. Day 1), vincristine (1 mg/M2 i.v. Day 1)
and prednisolone (50 mg orally daily Days
1-5. Ten patients were evaluable and in this
group there were 6 partial responses.
Although adriamycin is not reported to be
an effective single agent, the above combina-
tion certainly produced a higher response rate
than that reported from conventional chemo-
therapy in advanced malignant melanoma.
Further work will be aimed at defining the
active drugs in the combination. In conclu-
sion the combination of adriamycin, cyclo-
phosphamide, vincristine and prednisolone
produced 6/10 partial responses compared to
1/14 using conventional therapy with DTIC,
methyl CCNU and vincristine.
RAZOXANE/ARA-C IN THE TREAT-
MENT OF ADULT ACUTE LEUKAE-
MIA. K. HELLMANN, K. A. NEWTON and
J. G. HUMBLE, Departments of Oncology and
Haematology, Westminster Hospital, London.
Razoxane has shown actively in acute
lymphoblastic and in acute myeloblastic
leukaemia (AML) of children (Hellmann et
al., 1969, Brit: med. J., i, 822; Krepler and
Pawlowsky, 1975, Osterreichische Z. Onkol.,
2, 112). Since AML has a particularly poor
prognosis in the elderly, and because treat-
ment of this group of patients presents con-
siderable problems, razoxane was combined
with cytosine arabinoside (the mainstay of
AML treatment). The regime consisted of
razoxane 125 mg 3 x daily for 3 days and
Ara-C 1 mg/kg i.v. on the same 3 days. The
course was repeated every 5-7 days. Toxi-
city, if any, was chiefly haematological, but
when normal blood elements declined, they
began to recuperate after a few days. Of 5
patients with acute monocytic or myelo-
monocytic leukaemia, 1 did not respond, 3
had partial remissions and 1 had a complete
remission. The regime is suitable for out-
patient administration and no special nursing
care is required. Supportive care required
when patients were in hospital was minimal.
A striking feature of the response in 3 of the
patients was the rapidity ofonset ofthe blast
clearance of the blood. From wNhat is known
of the clinical activity of the two drugs it
would be most unlikely that the results so
far could have been obtained with either of
the drugs alone, but whether they potentiate
each other or are merely good additive agents
is not known as yet.
CHEMOTHERAPY FOR LOCALIZED
TESTICULAR TERATOMAS. K. H6FF-
KEN and C. G. SCHMIDT, Cancer Research
Campaign Laboratories, University ofNotting-
ham and Dept. of Internal Medicine (Cancer
Research), University ofEssen, WTest Germany.
26 patients with Stage II testicular tera-
tomas (metastases confined to retroperi-
toneal lymph nodes (RLN)) were treated by
cytostatic chemotherapy with or without
radiotherapy after retroperitoneal lymph
node dissection (RLD). Regimens consisted
ofboth single and combination chemotherapy.
In a retrospective analysis after a mean
follow-up time of 35 months (range 27-60
months) 420/ relapsed with distant meta-
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stases. Although not statistically significant
(X2 = 0-98; P = 0.30) 56% of Stage IIB
patients (considerable metastates to RLN;
partial RLD performed) showed dissemina-
tion, compared with only 350/0 of patients
with Stage IIA disease (minimal metastases
to RLN; total RLD performed). Median
relapse-free survival is not yet reached (5700
relapse- free survival after 5 years). Median
relapse-free interval was 15 months, com-
pared with 3 months, in a retrospective
analysis of patients being referred with wide-
spread disease after watch-policy only.
Median total survival is more than 60 months
as evaluated by life-table analysis (5-year
survival rate 710%). No difference was found
in patients given additional radiotherapy.
These results indicate a more favourable
outcome for patients being treated by adju-
vant chemotherapy than the historical prog-
nosis (5-year survival rate 40-500/). Prospec-
tive studies have to confirm these findings,
since historical data embody many variables,
thus not accurately reflecting differences
between untreated and cytostatically treated
patients with Stage II testicular teratomas.
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